Author's response to reviews
|
|
- Anna Pitts
- 5 years ago
- Views:
Transcription
1 Author's response to reviews Title: Contribution of Interferon Gamma Release Assays testing to the Diagnosis of Latent Tuberculosis Infection in HIV-Infected Patients: A comparison of QuantiFERON Gold in Tube, T-SPOT.TB and Tuberculin Skin Test Authors: José M. Ramos (jramosrincon@yahoo.es) Catalina Robledano (catirobledano@yahoo.es) Mar Masiá (marmasia@ya.com) Sofia Belda (sbelda_gas@hotmail.com) Sergio Padilla (sergiopadurr@gmail.com) Juan C. Rodríguez (jcrd65@gmail.com) Félix Gutiérrez (gutierrez_fel@gva.es) Version: 2 Date: 20 May 2012 Author's response to reviews: see over
2 Reviewer: Graham H Bothamley Major compulsory revisions 1. This paper assumes that a positive interferon-gamma release assay and latent tuberculosis (TB) are the same. However, the probability of latent tuberculosis is higher in subjects who have a positive test and have been exposed to TB. The paper should therefore be titled A comparison of QuantiFERON Gold in Tube, T-SPOT.TB and tuberculin in a cohort of HIV-infected subjects. The reviewer is right in his reflection, and we agree with him in the uncertainty of a positive IGRA in an HIV-infected patient with no other evidence of tuberculosis exposure (in the absence of a positive tuberculin test), as we state in the last paragraph of the Discussion. However, the limited available information suggests that these patients may have a higher risk of ulterior tuberculosis development. We have taken on board the reviewer suggestion and amended the title accordingly. The paper is now titled: Contribution of Interferon Gamma Release Assays testing to the Diagnosis of Latent Tuberculosis Infection in HIV-Infected Patients: A comparison of QuantiFERON Gold in Tube, T-SPOT.TB and Tuberculin Skin Test. 2. A Venn diagram would therefore be most useful to show how often the various tests coincide in terms of positives as defined by the manufacturers. The definition of a positive tuberculin skin test (5 mm) must be included in the abstract. According to the reviewer recommendation, we have included the Venn diagram (new Figure 1, and we have added a new sentence: TST induration > 5 mm was considered positive in the Methods section of the abstract. 3. The ultimate reason for doing these tests is to use preventive treatment to ensure that subjects do not develop TB and that sub-clinical TB is detected. The action taken for a positive test should therefore be included in the description of the study. We thank the reviewer for his valuable suggestion. We have included the following new paragraph in the Methods section (page 6, first paragraph): All patients with a positive tuberculin test who had not been previously treated, received chemoprophylaxis with isoniazide for 6-9 months. Patients with a positive IGRA plus a positive tuberculin also received isoniazide chemoprophylaxis. Patients with a positive IGRA but negative tuberculin test were individually managed by their doctors in charge, who decided to start chemoprophylaxis or not according to additional accompanying factors. 4. Those with contact with active TB should be examined separately. The degree of exposure should also be given.
3 Following the recommendation of the reviewer, we have examined separately the results of the test of the 302 patients with no past or current TB not positive TST according contact with active TB. For instance now there is two groups 209 patients without contact with patients wih TB and 93 patients with contact with patients with TB. We have included in the table 2. Now we have modified the table 2 the previous columns now are files, and the previous files now are columns. 5. Similarly those with previous TB should lead Table 1 in terms of the number of positive test. We have taken on board the valuable suggestion of the reviewer and analyzed separately patients with previous or current TB in a new column in Table Table 1 should be amended to include the criteria for giving preventive treatment - the categories patients with (or without) past or current TB or treatment for LTBI are too broad. We have changed this remaining category in Table 1 and Table 2 for Patients with positive TST. We also have changed this remaining category in the test. 7. Table 4 should be simplified to give a clear message and include only data, which show significant variation. According to the reviewer s recommendation, we have simplified the table 4 by including only significant variables. Discretionary Revision 1. There is increasing interest in the grey zone for the different tests. The data could be used to show how many are in these zones, perhaps using 5-15 mm for the tuberculin skin test. This could be combined with the number of indeterminate results and the CD4 cell count to complement the literature on these aspects. The reviewer raises again an interesting point, and we are grateful for his contribution to improve the paper. Unfortunately, the quantification of the induration with the tuberculin test was not recorded in all cases in our study, and therefore we cannot provide this information in the manuscript. Reviewer: Mengistu Legesse MAJOR COMPULSORY REVISIONS
4 - The authors found a much higher LTBI prevalence when using T-SPOT.TB compared to QFG or TST. Essentially, they conclude that the discrepancy must be due to a higher T-SPOT.TB sensitivity. Although this may well be true and previous studies support this finding, the authors should address the importance/reliability of USP Microscope compared to ELISPOT plate reader in measuring/counting SFU in the method part We thank the reviewer for his valuable suggestion. Accordingly, we have incorporated a new paragraph in the Discussion section: It should be stated, however, that we did not use the most reliable method for counting SFU, the automated ELISPOT plate reader, and therefore misclassification of some of our results can not be ruled out. - A higher rate of indeterminate results was found with the T-SPOT.TB than QFG. On the other hand, the authors discussed that T-SPOT.TB may be less affected by advanced immunosuppression than QFG test (which is not clear). Thus, the possible source of indeterminate results in T.SPOT.TB needs to be assessed /discussed Following the suggestion of the reviewer, we have included the main reasons explaining the number of indeterminate results with the T.SPOT.TB (page 12, second paragraph). We also included a new reference. It number is 22. We also change de number of the rest of the references. - More positive results were common in patients with past, current history of TB or LTBI by the three tests. What does this imply (re-infection, re-activation or persistent immune response)? How the authors define LTBI? What was the importance (objective) of including those individuals with past history of M. tuberculosis infection? These issues should be addressed more thoroughly in the introduction and discussion parts. We are grateful for the constructive comments of the reviewer. The past TB was referred by the patient or collected from clinical records. Current TB diagnosis was based on the results of clinical and radiologic examination and/or isolation of M. tuberculosis from sputum or other specimen. LTBI was defined by a previous positive TST performed in our clinic or in another clinic. The patients with past, current history of TB or LTBI had a higher frequency of positive tests presumably because of a persistent immune response. Those patients were included in the study as positive controls, to assess the yield and reliability of the tests in the subset of patients who retained persistent immune response. We have included this information in the Methods and Discussion sections (page 5, last paragraph and page 13, first paragraph). - The presentation and interpretation of results of factors associated with LTBI are not clear both in the text and in table 4. According to the reviewer recommendation we have simplified the table 4 by including only significant variables.
5 MINOR ESSENTIAL REVISIONS 1. Abstract Background: tells us the objective of the study rather than the rationale of the study We have taken on board the reviewer s suggestion, and have added two new sentences in the Background: Diagnosis and treatment of latent tuberculosis infection (LTBI) is the most effective strategy to control tuberculosis (TB) among patients with HIV infection. The tuberculin skin test (TST) was the only available method to identify LTBI. The aim of the present work was to Methods: indicate the period of the study We have included the period of the study in Methods: Prospective study from January 2009 to October 2010 carried out in consecutive patients cared for in a single institution in Spain. IGRAS and tuberculin skin test (TST) were performed simultaneously Results: the statistical difference between the positive results found using TST and QFG (12.3% VS 7.5%, P= 0.05) is not significant. even the difference between TST and T-SPOT.TB (12.3% VS 18.5%, P=0.04) is not strong. We have taken on board the reviewer s suggestion and have changed Compared with TST, more positive results were observed with T-SPOT.TB (12.3% vs. 18.5%; p=0.04) and less with QFG (12.3% vs. 7.5%; p=0.05) for TST, GFG and T-SPOT.TB were positive in 12.5%, 7.5% and 18.5% cases, respectively Among patients without past history of M. tuberculosis infection (n= 302), TST results were not available in 25 (8.3%), while 20 (6.6%) were positive by TST. I think the percentage (6.6%) should be re-calculated for those patients whose TST results are available (N= 277). This correction needs to be made through all the manuscript. We have recalculated the percentage of patients with positive TST, and corrected the old value through all the manuscript Mention some significantly associated factors like CD4 counts with the diagnostic positivity of LTBI Following the recommendation of the reviewer, we have added the factors associated with the diagnostic positivity of LTBI (Abstract, last sentence of the Results section): Patients with a CD4 cell count greater than 500 cells/µl and prior stay in prison were more likely to have a diagnosis of LTBI by TST and/or QFG and/or T.SPOT.TB (adjusted odds ratio [aor]: 3.76; 95% CI, ; and aor: 3.3; 95% CI, , respectively). 2. Background 2.1. Page 3, second paragraph, second line: Mycobacterium tuberculosis, needs to be abbreviated as M. tuberculosis in bracket.
6 We have abbreviated Mycobacterium tuberculosis accordingly 2.2. Page 4, first paragraph, line seven: In this investigation, patients with a broad spectrum of HIV disease were studied the meaning of patients with a broad spectrum of HIV disease is not clear. We have modified the sentence according to the recommendations of the reviewer: patients with a broad spectrum of HIV disease for. patients with different stages of HIV disease. 3. Methods 3.1 Page 4, second paragraph, was a treatment given when the IGRAs/TST results found positive? To explain the management of patients with LTBI, the following paragraph has been included: All patients with a positive tuberculin test who had not been previously treated received chemoprophylaxis with isoniazide for 6-9 months. Patients with a positive IGRA plus a positive tuberculin also received chemoprophylaxis. Patients with a positive IGRA but negative tuberculin test were individually managed by their doctors in charge, who decided to start chemoprophylaxis or not according to other accompanying factors Page 5, first paragraph, line 5, it is not clear how was the skin induration measured? We have taken on board the reviewer s suggestion, and we have rewritten the sentence: Induration was measured at hours after the inoculation. The size of the induration equal or higher than 5 mm was considered positive Page 5, second paragraph, it is unclear how blood samples were collected for QFG assay? Was it collected directly into each tube? According to the reviewer s recommendation we have clarified and re-written the sentence about the collection of the samples for the QFG assay For QFG, whole blood was collected from each patient and inoculated in three heparinized tubes of 1 ml each: one containing TB antigens (ESAT-6, CFP-10, and TB7.7), a positive control tube containing phytohemagglutinin, and a null control 3.4. Page 5, the same paragraph, how was the level of IFN- determined? was the interpretation made using software developed by the company? We have taken on board the reviewer s suggestion, and added the following sentence: Optical densities were interpreted by using specific software provided by the manufacturer 3.5. Page 6, first paragraph, last line, references are needed for the reliability of USP Microscope
7 We have modified and added the reference of the software of USB Microscope according your recommendations. The new sentence says: The SFU were counted with an Veho - VMS- 001 USB Microscope with the Microcapture software [16] Reference: [16] User instructions. Microcapture Software. Available in: We have changed the references because we have added a new reference Was the SFU count performed by one person? We have added: SFU were counted by one observer in case of doubt by two observers 4. Results 4.1. Page 8, first paragraph, was there any unresponsive (anergy) result by the TST? (as anergy is common in HIV-infected individuals) The reviewer raises an interesting question. Unfortunately, no additional tests were performed to quantify how many of the negative results of the TST were indeed patients with no LTBI or anergic patients. We have included a sentence at the end of the Discussion section addressing this: The rate of anergic patients was also unknown because no additional skin tests to the TST were performed 4.2. page 7, last paragraph, last line, needs to be corrected as Table 1 shows... those patients with and with no... We thank the reviewer for making us aware of this mistake. We have corrected the sentence: Table 1 shows the differences between those patients with and with no past or current TB or positive TST Page 8, second paragraph, Compared with TST, more positive results were observed with T-SPOT.TB according to manufacturer s criteria (12.3% versus 18.5%; p=0.04) and less with QFG (12.3% versus 7.5%; p=0.05). The number of indeterminate or invalid results was lower for QFG than for T-SPOT.TB (2.7% versus 7.2%; p=0.002) We have taken on board the reviewer s suggestion and have changed Compared with TST, more positive results were observed with T-SPOT.TB (12.3% vs. 18.5%; p=0.04) and less with QFG (12.3% vs. 7.5%;p=0.05) for TST, GFG and T-SPOT.TB were positive in 12.5%, 7.5% and 18.5% cases, respectively As it is described in data analysis section the p-values are generated from Pearson chi-square. However, the appropriate test statistic is McNemar s chi-square. Authors should reanalyzed this part of the data appropriately and also indicate the method used here in the data analysis section.
8 We have re-analyzed data specified by the reviewer by using McNemar s test, and indicated it in Methods section 4.5. Page 8, last paragraph, the percentage (6.6%) of TST positive individuals should be corrected (or describe, how it was calculated ). According to the recommendations of the reviewer, we have changed the denominator to 277. The new percentage obtained of positive TST individuals of 7.2% has been changed all through the manuscript Page 9, Is the OR mentioned in the text an adjusted or crude? What is associated with what in Table 4? I can not see the logistic regression results (OR or 95%CI). In table 4, only univariate analyses have been included. Associations in the table represent the factors linked with positive results for each test. ORs adjusted for all significant variables of univariate analyses have only been shown in the text. For clarification purposes, we have incorporated this information in the footnote of Table 4. We have added in the statistical analysis section that the OR are adjusted OR (aor). 4.7 Under each table, it is described that Date are no (%) of patients, what is a date? We are sorry for the mistake. We have changed Date are no (%) for Data are no (%) of patients. 4.8 Table 3, column 2, row 4, is the range from ? Please see also row 6, range from ? We thank the reviewer, it has been also a mistake, We have modified in column 2, row 4 the range (it should say: ), and row in 6 ( ). 4.9 is BCG defined as Bacille Calmette-Guérin or Bacille de Calmette et Guérin? Bacille de Calmette et Guérin is in French and Bacille Calmette-Guérin in English. We have taken on board the reviewer s suggestion and have changed from French language to English 5.1. Discussion 5.1 Page 11, first paragraph, line 8, in studies carried out... the sensitivity was 94% for T-SPOT.TB (Ref 22), and 67% for QFG (Ref 23) it is not appropriate to compare the sensitivities of the two tests in two independent studies. The results would be varied, if both tests would have been used in the same study According to the reviewer recommendation we have modified the original sentence and we have transformed it into two sentences. In studies carried out in countries with low prevalence of TB, sensitivity was 94% for T-SPOT.TB [22]. In the study of Sauzullo et al the sensitivity of QFG was 67%, not higher than that of TST in head-to-head comparison [25].
Peggy Leslie-Smith, RN
Peggy Leslie-Smith, RN EMPLOYEE HEALTH DIRECTOR - AVERA TRAINING CONTENT 1. South Dakota Regulations 2. Iowa Regulations 3. Minnesota Regulations 4. Interferon Gamma Release Assay (IGRA)Testing 1 SOUTH
More informationTB Intensive Tyler, Texas December 2-4, 2008
TB Intensive Tyler, Texas December 2-4, 2008 Interferon Gamma Releasing Assays: Diagnosing TB in the 21 st Century Peter Barnes, MD December 2, 2008 TOPICS Use of interferon-gamma release assays (IGRAs)
More informationTitle: Role of Interferon-gamma Release Assays in the Diagnosis of Pulmonary Tuberculosis in Patients with Advanced HIV infection
Author's response to reviews Title: Role of Interferon-gamma Release Assays in the Diagnosis of Pulmonary Tuberculosis in Patients with Advanced HIV infection Authors: Adithya Cattamanchi (acattamanchi@medsfgh.ucsf.edu)
More informationEvaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Interferon Gamma Release Assays: Understanding the Test David Griffith, BA, MD April 11, 2014 David Griffith, BA, MD has the following
More informationVariation in T-SPOT.TB spot interpretation between independent observers of different laboratories
8 Variation in T-SPOT.TB spot interpretation between independent observers of different laboratories Willeke P.J. Franken 1, Steven Thijsen 2, Ron Wolterbeek 3, John J.M. Bouwman 2, Hanane el Bannoudi
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Interferon Gamma Release Assays (IGRA s) Lisa Armitige, MD, PhD October 16, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Interferon Gamma Release Assays Lisa Armitige, MD, PhD November 12, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 IGRA s and Their Use in TB Nurse NCM Lisa Armitige, MD, PhD July 18, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationTitle: Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study
Author's response to reviews Title: Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study Authors: Delia Goletti (d.goletti@tiscali.it)
More informationTB Prevention Who and How to Screen
TB Prevention Who and How to Screen 4.8.07. IUATLD 1st Asia Pacific Region Conference 2007 Dr Cynthia Chee Dept of Respiratory Medicine / TB Control Unit Tan Tock Seng Hospital, Singapore Cycle of Infection
More informationTechnical Bulletin No. 172
CPAL Central Pennsylvania Alliance Laboratory QuantiFERON -TB Gold Plus Assay Contact: J Matthew Groeller, MPA(HCM), MT(ASCP), 717-851-4516 Operations Manager, Clinical Pathology, CPAL Jennifer Thebo,
More informationBarbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast
Practical Aspects for Using the Interferon Gamma Release Assay (IGRA) Test Live Webinar July 14, 2017 Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and
More informationUse of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING -
Use of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING - Date and time: 20-21 July 2010, 09:00 18:00 Venue: Salle B, WHO-HQ, Geneva, Switzerland
More informationTargeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000
More informationUnderstanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010
Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 What is Latent TB Infection (LTBI)? Traci Hadley, RN October 5, 2010 LTBI or TB Disease? Presented by : Traci Hadley, RN
More informationSelf-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Targe te d Te s ting and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control
More informationNorthwestern Polytechnic University
Clinical Tuberculosis Assessment by Health Care Provider Clinicians should review and verify the information in the Tuberculosis (TB) Screening Questionnaire (attached). Persons answering YES to any questions
More informationThe Most Widely Misunderstood Test of All
The Most Widely Misunderstood Test of All Lee B. Reichman, MD, MPH NJMS Global Tuberculosis Institute History of Treatment of Latent Tuberculosis Infection For more than 4 decades, treatment of persons
More informationLATENT TUBERCULOSIS. Robert F. Tyree, MD
LATENT TUBERCULOSIS Robert F. Tyree, MD 1 YK TB OFFICERS Ron Bowerman Elizabeth Roll Mien Chyi (Pediatrics) Cindi Mondesir (Pediatrics) The new guys: Philip Johnson Robert Tyree 2009 CDC TB CASE DEFINITION
More informationMaking the Diagnosis of Tuberculosis
Making the Diagnosis of Tuberculosis Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Testing for TB Infection Targeted Testing: Key Points Test only if plan for ensuring treatment De-emphasizes
More informationUse of an Interferon- Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients*
Original Research MYCOBACTERIAL DISEASE Use of an Interferon- Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients* Daniel Brodie, MD; David J. Lederer, MD, MS; Jade S. Gallardo,
More informationThorax Online First, published on December 8, 2009 as /thx
Thorax Online First, published on December 8, 2009 as 10.1136/thx.2009.119677 Title Page Cost effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the Quantiferon-TB gold
More informationTargeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease
Self-Study Study Modules on Tuberculosis Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease 1 Module 3: Objectives At completion of this module, learners will
More informationT-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS
T-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS Kiatichai Faksri 1, 4, Wipa Reechaipichitkul 2, 4, Wilailuk Pimrin
More informationUsing Interferon Gamma Release Assays for Diagnosis of TB Infection
Learning Objectives Using Interferon Gamma Release Assays for Diagnosis of TB Infection 1. Describe available Interferon Gamma Release Assay tests for TB infection and how they work. 2. Understand interpretation
More informationTesting for TB. Bart Van Berckelaer Territory Manager Benelux. Subtitle
Testing for TB Bart Van Berckelaer Territory Manager Benelux Subtitle Agenda TB infection pathway TB immunisation Testing options Pre lab considerations of the whole blood ELISA test The T-SPOT.TB test
More informationTitle: Socioeconomic conditions and number of pain sites in women
Author's response to reviews Title: Socioeconomic conditions and number of pain sites in women Authors: Finn E Skjeldestad (fisk@fhi.no) Toril Rannestad (Toril.Rannestad@hist.no) Version: 2 Date: 17 January
More informationCHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]
CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT] QUESTION: : Which children in the United States should get a tuberculin skin test? Do questionnaires really work? Jeffrey
More informationInterferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients
NDT Advance Access published January 22, 2009 Nephrol Dial Transplant (2009) 1 of 5 doi: 10.1093/ndt/gfn748 Original Article Interferon-gamma release assays versus tuberculin skin testing for detection
More informationUC DavisTB Screening Requirement: How to submit your TB Health Assessment Form
UC DavisTB Screening Requirement: How to submit your TB Health Assessment Form Step 1 If after completing the TB Risk Screening you are found to be at high risk, you must complete the Tuberculosis (TB)
More informationEffect of prolonged incubation time on the results of the QuantiFERON TB Gold In-Tube assay for the diagnosis of latent tuberculosis infection
CVI Accepts, published online ahead of print on 3 July 2013 Clin. Vaccine Immunol. doi:10.1128/cvi.00290-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 Effect of prolonged
More informationESCMID Online Lecture Library. by author
Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with
More informationPREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal
PREVENTION OF TUBERCULOSIS Dr Amitesh Aggarwal 25 to 50 % of persons exposed to intimate contact with active PTB - latent infection with TB. Exposure to index case for 12 hours - high risk of infection.
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director, SF and North Coast AETC March 13, 2014 ACCREDITATION STATEMENT:
More informationDetecting latent tuberculosis using interferon gamma release assays (IGRA)
Detecting latent tuberculosis using interferon gamma release assays (IGRA) American Society for Microbiology June 2017 Edward Desmond, Ph.D., D (ABMM) San Lorenzo, CA Edward Desmond has no financial connections
More informationDiabetes and Tuberculosis: A Practical Approach to Diagnosis and Treatment
Diabetes and Tuberculosis: A Practical Approach to Diagnosis and Treatment Michael Lauzardo, MD MSc Chief, Division of Infectious Diseases and Global Medicine Director, Southeastern National Tuberculosis
More informationCUSOM Student Health Immunization Requirements
CUSOM Student Health Immunization Requirements Regulatory and legislative authorities require that students demonstrate immunization, immunity and/or protection from multiple contagious diseases before
More informationTitle:Modern contraceptive use among sexually active men in Uganda: Does discussion with a health worker matter?
Author's response to reviews Title:Modern contraceptive use among sexually active men in Uganda: Does discussion with a health worker matter? Authors: Allen Kabagenyi Ms. (allenka79@yahoo.com) Patricia
More informationTUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of
TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of Health and Mental Hygiene TODAY S PRESENTATION Epidemiology
More informationApproaches to LTBI Diagnosis
Approaches to LTBI Diagnosis Focus on LTBI October 8 th, 2018 Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES I have no disclosures or conflicts
More information2016 OPAM Mid-Year Educational Conference, Sponsored by AOCOPM Sunday, March 13, 2016
Learning Objectives Tuberculosis Case Discussions: Evaluation for Tuberculosis Infection Melissa C. Overman, DO, MPH, CHES, FAOCOPM Describe appropriate technique for TST placement, reading and interpretation
More informationProgrammatic management of LTBI : a two pronged approach for ending the TB epidemic. Haileyesus Getahun Global TB Programme WHO/HQ
Programmatic management of LTBI : a two pronged approach for ending the TB epidemic Haileyesus Getahun Global TB Programme WHO/HQ What is latent TB infection? A state of persistent immune response to stimulation
More information2017/2018 Annual Volunteer Tuberculosis Notice
Lewis Center for Educational Research Academy for Academic Excellence Norton Science and Language Academy Business Offices 17500 Mana Road Apple Valley, CA 92307 E-mail: hr@lcer.org 760-946-5414 Fax 760-946-9193
More informationPrimer on Tuberculosis (TB) in the United States
Primer on Tuberculosis (TB) in the United States The purpose of this primer is to provide instructors who have no prior background in TB research or clinical care with basic knowledge that they may find
More informationA Clinician s Perspective: Improving Rheumatology Patient Care Using the T-SPOT.TB Test
A Clinician s Perspective: Improving Rheumatology Patient Care Using the T-SPOT.TB Test Solomon Forouzesh, MD, FACD, FACR Medical Director Arthritis Care & Treatment Center Clinical Associate Professor
More informationIdentifying TB co-infection : new approaches?
Identifying TB co-infection : new approaches? Charoen Chuchottaworn MD. Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH Primary tuberculosis Natural history
More informationNew Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents
New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea
More informationATTACHMENT 2. New Jersey Department of Health Tuberculosis Program FREQUENTLY ASKED QUESTIONS
1. QUESTION Is it required to submit the Annual Report of TB Testing in Schools Form (TB-57) to the New Jersey Department of Health,? NO. The TB-57 form is completed by the school nurse and kept on-site
More informationEvaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI)
Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI) CURTIS FOWLER MPT,PA C ASSISTANT CLINICAL PROFESSOR UNIVERSITY OF THE PACIFIC Learning objectives Recognize the appropriate
More informationQualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis treatment
ORIGINAL ARTICLE Korean J Intern Med 217;32:32-38 https://doi.org/1.394/kjim.216.199 Qualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director SF, North Coast and East Bay AETC January 8, 2015 ACCREDITATION
More informationAPSR RESPIRATORY UPDATES
APSR RESPIRATORY UPDATES Volume 5, Issue 2 Newsletter Date: February 2013 APSR EDUCATION PUBLICATION Inside this issue: Tuberculosis Multidrug-resistant pulmonary tuberculosis treatment regimens and patient
More informationTB Update: March 2012
TB Update: March 2012 David Schlossberg, MD, FACP Medical Director, TB Control Program Philadelphia Department of Public Health 1 TB Update: March 2012 IGRAs vs TST LTBI A New Regimen NAATs What is Their
More informationInterferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients
Nephrol Dial Transplant (2009) 24: 1952 1956 doi: 10.1093/ndt/gfn748 Advance Access publication 22 January 2009 Interferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis
More informationEvidence-based use of the new diagnostic tools for TB-infection
Evidence-based use of the new diagnostic tools for TB-infection Roland Diel, MD, MPH German Central Committee against Tuberculosis, Germany 20. Tuberkulose-Symposium in Münchenwiler, 24 th March 2011 1
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationDimitrios Vassilopoulos,* Stamatoula Tsikrika, Chrisoula Hatzara, Varvara Podia, Anna Kandili, Nikolaos Stamoulis, and Emilia Hadziyannis
CLINICAL AND VACCINE IMMUNOLOGY, Dec. 2011, p. 2102 2108 Vol. 18, No. 12 1556-6811/11/$12.00 doi:10.1128/cvi.05299-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparison
More informationThe Challenges and Pitfalls in Diagnosing or Misdiagnosing Tuberculosis: Are the Days of TB Skin Tests Over?
The Challenges and Pitfalls in Diagnosing or Misdiagnosing Tuberculosis: Are the Days of TB Skin Tests Over? ROY F. CHEMALY, MD, MPH, FIDSA, FACP PROFESSOR OF MEDICINE DIRECTOR, INFECTION CONTROL SECTION
More informationAuthor's response to reviews
Author's response to reviews Title: A multicentre, double-blind, randomised, controlled, parallel-group study of the effectiveness of a pharmacist-acquired medication history in an emergency department
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
TB Partial Update Appendix 1 - Scope NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Tuberculosis: interferon gamma tests for the diagnosis of latent tuberculosis (partial
More informationScreening for Tuberculosis Infection. Harlingen, TX. Linda Dooley, MD has the following disclosures to make:
TB Infection Diagnosis Recommendations Talk Developed by Lisa Y. Armitige, MD, PhD Medical Consultant, Heartland National TB Center Associate Professor Internal Medicine/Pediatrics/Infectious Disease UT
More informationRESEARCH NOTE QUANTIFERON -TB GOLD IN-TUBE TEST FOR DIAGNOSING LATENT TUBERCULOSIS INFECTION AMONG CLINICAL-YEAR THAI MEDICAL STUDENTS
Southeast Asian J Trop Med Public Health RESEARCH NOTE QUANTIFERON -TB GOLD IN-TUBE TEST FOR DIAGNOSING LATENT TUBERCULOSIS INFECTION AMONG CLINICAL-YEAR THAI MEDICAL STUDENTS Benjawan Phetsuksiri 1, Somchai
More informationUtility of Interferon- Release Assay Results to Monitor Anti- Tubercular Treatment in Adults and Children
Clinical Therapeutics/Volume 34, Number 5, 2012 Utility of Interferon- Release Assay Results to Monitor Anti- Tubercular Treatment in Adults and Children Elena Chiappini, MD, PhD, Francesca Fossi, MD,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Tuberculosis: interferon gamma tests for the diagnosis of latent tuberculosis (partial update) 1.1 Short title Tuberculosis
More informationTitle: Home Exposure to Arabian Incense (Bakhour) and Asthma Symptoms in Children: A Community Survey in Two Regions in Oman
Author's response to reviews Title: Home Exposure to Arabian Incense (Bakhour) and Asthma Symptoms in Children: A Community Survey in Two Regions in Oman Authors: Omar A Al-Rawas (orawas@squ.edu.om) Abdullah
More informationInvestigation of false-positive results by the QuantiFERON-TB Gold In-Tube assay
JCM Accepts, published online ahead of print on 11 July 2012 J. Clin. Microbiol. doi:10.1128/jcm.00730-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Investigation of false-positive
More informationMædica - a Journal of Clinical Medicine
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Prospective Comparison of Two Brands of Tuberculin Skin Tests and Quantiferon-TB Gold in-tube Assay Performances for Tuberculosis Infection in Hospitalized
More informationCOMPARISON OF TWO INTERFERON-G ASSAYS AND
3 COMPARISON OF TWO INTERFERON-G ASSAYS AND CONTACTS Sandra M. Arend 1, Steven F.T. Thijsen 2, Eliane M.S. Leyten 1, John J.M. Bouwman 2, Willeke P.J. Franken 1 3, Frank G.J. Cobelens 4,5, Arend-Jan van
More informationCritical Evaluation of Tuberculosis Diagnostic Tests in Low- and High- Burden Settings
Critical Evaluation of Tuberculosis Diagnostic Tests in Low- and High- Burden Settings by John Metcalfe Dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy
More informationGuidance for Identifying Risk Factors for Mycobacterium tuberculosis (MTB) During Evaluation of Potential Living Kidney Donors
Summary and Goals On November 13, 2012, the OPTN/UNOS Board of Directors approved a requirement that all potential living kidney donors undergo evaluation for infection with Mycobacterium tuberculosis
More informationDiagnosis Latent Tuberculosis. Disclosures. Case
Diagnosis Latent Tuberculosis Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention September 2016 1 Disclosures
More informationConflict of Interest Disclosures:
Mady Slater, M.D. Stanford University Medical Center Division of Infectious Diseases 04/23/14 WOEMA webinar Conflict of Interest Disclosures: I have no financial relationships with commercial entities
More informationDiagnosis and Medical Case Management of Latent TB. Bryan Rock, MD April 27, 2010
TB Nurse Case Management Lisle, Illinois April 27-28, 28 2010 Diagnosis and Medical Case Management of Latent TB Infection Bryan Rock, MD April 27, 2010 DIAGNOSIS AND MANAGEMENT OF LATENT TUBERCULOSIS
More informationTuberculosis and TNF Inhibitors
Tuberculosis and TNF Inhibitors Sundari Mase MD, MPH Medical Team Lead CDC/DTBE/FSEB January 18, 2011 Objectives Discuss the association between and epidemiology of TNF inhibitors and TB Discuss the challenges
More informationLatent tuberculosis infection
EXECUTIVE SUMMARY Latent tuberculosis infection Updated and consolidated guidelines for programmatic management Executive summary Latent tuberculosis infection (LTBI) is defined as a state of persistent
More informationClinical Study Consistency of Mycobacterium tuberculosis-specific Interferon-Gamma Responses in HIV-1-Infected Women during Pregnancy and Postpartum
Infectious Diseases in Obstetrics and Gynecology Volume 2012, Article ID 950650, 7 pages doi:10.1155/2012/950650 Clinical Study Consistency of Mycobacterium tuberculosis-specific Interferon-Gamma Responses
More informationAnalysis of an Interferon-Gamma Release Assay for Monitoring the Efficacy of Anti-Tuberculosis Chemotherapy
Jpn. J. Infect. Dis., 64, 133-138, 2011 Original Article Analysis of an Interferon-Gamma Release Assay for Monitoring the Efficacy of Anti-Tuberculosis Chemotherapy Kiyoko Takayanagi, Misako Aoki, Kumiko
More informationComparison of Quantiferon-TB Gold With Tuberculin Skin Test for Detecting Latent Tuberculosis Infection Prior to Liver Transplantation
American Journal of Transplantation 2007; 7: 2797 2801 Blackwell Munksgaard C 2007 The Authors Journal compilation C 2007 The American Society of Transplantation and the American Society of Transplant
More informationTitle: Prediction of HIV-1 virus-host protein interactions using virus and host sequence motifs
Author's response to reviews Title: Prediction of HIV-1 virus-host protein interactions using virus and host sequence motifs Authors: Perry PE Evans (evansjp@mail.med.upenn.edu) Will WD Dampier (wnd22@drexel.edu)
More informationLatent Tuberculosis Infection Reporting Instructions for Civil Surgeons Using CalREDIE Provider Portal
Latent Tuberculosis Infection Reporting Instructions for Civil Surgeons Using CalREDIE Provider Portal Civil surgeons are required to report tuberculosis (TB) screening outcomes that result in latent TB
More informationDEPARTMENT OF THE ARMY OFFICE OF THE SURGEON GENERAL 5109 LEESBURG PIKE FALLS CHURCH, VA
DEPARTMENT OF THE ARMY OFFICE OF THE SURGEON GENERAL 5109 LEESBURG PIKE FALLS CHURCH, VA 22041-3258 DASG-PPM-NC r% 5 SEP 2008 MEMORANDUM FOR SEE DISTRIBUTION SUBJECT: Supplemental guidance for the Army
More informationValidity of interferon-c-release assays for the diagnosis of latent tuberculosis in haemodialysis patients
ORIGINAL ARTICLE BACTERIOLOGY Validity of interferon-c-release assays for the diagnosis of latent tuberculosis in haemodialysis patients W. K. Chung 1,2, Z. L. Zheng 1, J. Y. Sung 1, S. Kim 1,H.H.Lee 1,
More informationA Mobile Health Intervention Utilizing Community Partnership to Improve Access to Latent Tuberculosis Infection Treatment
A Mobile Health Intervention Utilizing Community Partnership to Improve Access to Latent Tuberculosis Infection Treatment Cassandra Garcia, MSN, RN, FNP-BC Mobile Clinic Provider Texas Children s Mobile
More informationContracts Carla Chee, MHS May 8, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Contracts Carla Chee, MHS May 8, 2012 Carla Chee, MHS has the following disclosures to make: No conflict of interests No relevant
More informationAdachi et al. SpringerPlus 2013, 2:440 a SpringerOpen Journal
Adachi et al. SpringerPlus 2013, 2:440 a SpringerOpen Journal RESEARCH Open Access Tuberculosis examination using whole blood interferon-gamma release assay among health care workers in a Japanese hospital
More informationPredictive Value of interferon-gamma release assays for incident active TB disease: A systematic review
Predictive Value of interferon-gamma release assays for incident active TB disease: A systematic review Lele Rangaka University of Cape Town, South Africa mxrangaka@yahoo.co.uk 1 The 3 I s Isoniazid preventive
More informationORIGINAL ARTICLE. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients
ERJ Express. Published on July 25, 2007 as doi: 10.1183/09031936.00040007 ORIGINAL ARTICLE Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients Yoshihiro Kobashi, Keiji Mouri, Yasushi
More informationStudent Health Requirements Master of Arts, Biomedical Sciences Program
Student Health Requirements Master of Arts, Biomedical Sciences Program All students in medically related programs, just as physicians in practice, are required to be current with required immunizations
More informationIGRAs evolution. José Domínguez
MESA: Novedades en métodos diagnósticos y en tratamiento Moderadores: Fernando Alcaide. Hospital Universitari de Bellvitge. L Hospitalet de Llobregat. Julià González. Hospital Clínic i Provincial de Barcelona.
More informationNew Standards for an Old Disease:
New Standards for an Old Disease: Practical Implications of the TB Standards TB Prevention and Control Saskatchewan September 16, 2015 Practical Implications of the TB Standards Learning Objectives At
More informationCHAPTER 3: DEFINITION OF TERMS
CHAPTER 3: DEFINITION OF TERMS NOTE: TB bacteria is used in place of Mycobacterium tuberculosis and Mycobacterium tuberculosis complex in most of the definitions presented here. 3.1 Acid-fast bacteria
More informationDiagnosis of tuberculosis
Diagnosis of tuberculosis Madhukar Pai, MD, PhD Assistant Professor, Epidemiology McGill University, Montreal, Canada madhukar.pai@mcgill.ca Global TB Case Detection A major concern 2.6 million new smear
More informationReceived 8 February 2007/Returned for modification 20 March 2007/Accepted 10 April 2007
CLINICAL AND VACCINE IMMUNOLOGY, June 2007, p. 714 719 Vol. 14, No. 6 1556-6811/07/$08.00 0 doi:10.1128/cvi.00073-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Comparison of
More informationDiagnosing latent tuberculosis infection in haemodialysis patients: T-cell based assay (T-SPOT.TB) or tuberculin skin test?
Nephrol Dial Transplant (2012) 27: 1645 1650 doi: 10.1093/ndt/gfr516 Advance Access publication 19 September 2011 Diagnosing latent tuberculosis infection in haemodialysis patients: T-cell based assay
More informationDiagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017
Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationThe World Health Organization s strategy. Enhanced diagnosis of HIV-1-associated tuberculosis by relating T-SPOT.TB and CD4 counts
Eur Respir J 21; 36: 594 6 DOI: 1.1183/931936.17159 CopyrightßERS 21 Enhanced diagnosis of HIV-1-associated tuberculosis by relating T-SPOT.TB and CD4 counts T. Oni*,#, J. Patel ", H.P. Gideon*, R. Seldon*,
More informationTitle:Continuity of GP care is associated with lower use of complementary and alternative medical providers A population-based cross-sectional survey
Author's response to reviews Title:Continuity of GP care is associated with lower use of complementary and alternative medical providers A population-based cross-sectional survey Authors: Anne Helen Hansen
More informationNIHR HTA Programme. 09 July 2013
NIHR HTA Programme 09 July 2013 The NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC), based at the University of Southampton, manages evaluation research programmes and activities for the
More information